OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406.
Publication
, Journal Article
Janne, PA; Wang, X; Socinski, MA; Crawford, J; Gu, L; Capelletti, M; Edelman, MJ; Villalona-Calero, MA; Kratzke, RA; Vokes, E; Miller, VA
Published in: JOURNAL OF THORACIC ONCOLOGY
June 1, 2011
Duke Scholars
Published In
JOURNAL OF THORACIC ONCOLOGY
EISSN
1556-1380
ISSN
1556-0864
Publication Date
June 1, 2011
Volume
6
Issue
6
Start / End Page
S447 / S448
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Gu, L., Capelletti, M., … Miller, V. A. (2011). OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406. JOURNAL OF THORACIC ONCOLOGY, 6(6), S447–S448.
Janne, Pasi A., Xiaofei Wang, Mark A. Socinski, Jeffrey Crawford, Lin Gu, Marzia Capelletti, Martin J. Edelman, et al. “OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406.” JOURNAL OF THORACIC ONCOLOGY 6, no. 6 (June 1, 2011): S447–48.
Janne PA, Wang X, Socinski MA, Crawford J, Gu L, Capelletti M, et al. OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406. JOURNAL OF THORACIC ONCOLOGY. 2011 Jun 1;6(6):S447–8.
Janne, Pasi A., et al. “OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406.” JOURNAL OF THORACIC ONCOLOGY, vol. 6, no. 6, LIPPINCOTT WILLIAMS & WILKINS, June 2011, pp. S447–48.
Janne PA, Wang X, Socinski MA, Crawford J, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke RA, Vokes E, Miller VA. OUTCOME OF ADVANCED NSCLC PATIENTS WITH EGFR EXON 19 AND 21 MUTATIONS TREATED WITH ERLOTINIB (E) ALONE OR IN COMBINATION WITH CARBOPLATIN/PACLITAXEL (CP) IN CALGB 30406. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2011 Jun 1;6(6):S447–S448.
Published In
JOURNAL OF THORACIC ONCOLOGY
EISSN
1556-1380
ISSN
1556-0864
Publication Date
June 1, 2011
Volume
6
Issue
6
Start / End Page
S447 / S448
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology